Skip to main content

Douglas William Bonhaus, PhD

Chief Operating/Science Officer at Neuropore Therapies Inc.

Location: San Diego, CA United States

Douglas William Bonhaus, PhD, has more than 20 years of experience in the pharmaceutical industry leading drug-discovery efforts targeting neuropsychiatric and neurological disorders. Prior to assuming leadership of drug-discovery at Neuropore Therapies, Dr. Bonhaus led drug discovery groups at Syntex Research, Roche Biosciences and ACADIA Pharmaceuticals. Significant drug-discovery accomplishments include leading teams that discovered a 5-HT2B receptor antagonist for the prevention of migraine; a 5-HT6 receptor antagonist for the treatment of Alzheimer’s disease and; a muscarinic receptor partial agonist for the treatment of schizophrenia. In addition to leading drug discovery efforts, Dr. Bonhaus has successful applied for extramural funding from federal granting agencies, is an inventor on several patents and has co-authored more than 100 publications in peer-reviewed journals.  


Associated Grants

  • Development of the Alpha-Synuclein Stabilizer NPT200-11 for the Treatment of Parkinson’s Disease

    2013


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.